Andrey G Korshunov

List of Publications by Year
in descending order

259 papers	46,649 citations	1888 102 h-index	1980 206 g-index
273 all docs	273 docs citations	273 times ranked	33593 citing authors

#	Article	IF	Citations
1	Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study. Clinical Cancer Research, 2022, 28, 116-128.	3.2	8
2	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. Acta Neuropathologica Communications, 2022, 10, 5.	2.4	12
3	Predictive modeling of resistance to SMO-inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma. Neuro-Oncology Advances, 2022, 4, vdac026.	0.4	1
4	Oligosarcomas, IDH-mutant are distinct and aggressive. Acta Neuropathologica, 2022, 143, 263-281.	3.9	18
5	Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression. Acta Neuropathologica, 2022, 144, 339-352.	3.9	5
6	CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model. Oncogene, 2021, 40, 396-407.	2.6	35
7	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathologica, 2021, 141, 85-100.	3.9	52
8	Accurate calling of KIAA1549â€BRAF fusions from DNA of human brain tumours using methylation arrayâ€based copy number and gene panel sequencing data. Neuropathology and Applied Neurobiology, 2021, 47, 406-414.	1.8	12
9	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. Neuro-Oncology, 2021, 23, 34-43.	0.6	75
10	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma. Neuro-Oncology Advances, 2021, 3, vdab002.	0.4	2
11	ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma. Neuro-Oncology Advances, 2021, 3, vdab030.	0.4	2
12	A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors. Cancers, 2021, 13, 230.	1.7	13
13	Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation. Acta Neuropathologica Communications, 2021, 9, 20.	2.4	23
14	Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator. Neuro-Oncology, 2021, 23, 1576-1585.	0.6	7
15	Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). Acta Neuropathologica, 2021, 141, 605-617.	3.9	36
16	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro-Oncology, 2021, 23, 1360-1370.	0.6	46
17	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	0.8	40
18	The age of adult pilocytic astrocytoma cells. Oncogene, 2021, 40, 2830-2841.	2.6	6

#	Article	IF	Citations
19	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. Acta Neuropathologica, 2021, 142, 179-189.	3.9	24
20	Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model. Neuro-Oncology, 2021, 23, 2028-2041.	0.6	7
21	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	0.6	22
22	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. Acta Neuropathologica, 2021, 142, 841-857.	3.9	36
23	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	3.9	33
24	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	3.9	34
25	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. Nature Communications, 2021, 12, 5530.	5.8	24
26	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta Neuropathologica, 2021, 142, 1065-1069.	3.9	16
27	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. Acta Neuropathologica, 2021, 142, 873-886.	3.9	12
28	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	5.8	237
29	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Science Translational Medicine, 2021, 13, eabc0497.	5.8	29
30	Co-activation of Sonic hedgehog and Wnt signaling in murine retinal precursor cells drives ocular lesions with features of intraocular medulloepithelioma. Oncogenesis, 2021, 10, 78.	2.1	0
31	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathologica, 2020, 139, 193-209.	3.9	83
32	Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. Acta Neuropathologica, 2020, 139, 403-406.	3.9	9
33	YAP1-fusions in pediatric NF2-wildtype meningioma. Acta Neuropathologica, 2020, 139, 215-218.	3.9	45
34	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. Acta Neuropathologica, 2020, 139, 243-257.	3.9	50
35	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. Acta Neuropathologica, 2020, 139, 583-596.	3.9	13
36	Diffuse glioneuronal tumour with oligodendrogliomaâ€like features and nuclear clusters (DGONC) â€“ a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. Neuropathology and Applied Neurobiology, 2020, 46, 422-430.	1.8	51

#	Article	IF	Citations
37	Mosaic trisomy of chromosome 1q in human brain tissue associates with unilateral polymicrogyria, very early-onset focal epilepsy, and severe developmental delay. Acta Neuropathologica, 2020, 140, 881-891.	3.9	28
38	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell, 2020, 183, 1617-1633.e22.	13.5	93
39	Functional loss of a noncanonical BCORâ€“PRC1.1 complex accelerates SHH-driven medulloblastoma formation. Genes and Development, 2020, 34, 1161-1176.	2.7	16
40	Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype. Nature Communications, 2020, 11, 6434.	5.8	48
41	An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data. Acta Neuropathologica, 2020, 140, 237-239.	3.9	5
42	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature, 2020, 580, 396-401.	13.7	94
43	ETMR: a tumor entity in its infancy. Acta Neuropathologica, 2020, 140, 249-266.	3.9	47
44	Pilocytic astrocytoma demethylation and transcriptional landscapes link bZIP transcription factors to immune response. Neuro-Oncology, 2020, 22, 1327-1338.	0.6	10
45	Pan-cancer analysis of whole genomes. Nature, 2020, 578, 82-93.	13.7	1,966
46	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. Journal of Clinical Oncology, 2020, 38, 2028-2040.	0.8	58
47	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	7.7	157
48	MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathologica, 2019, 138, 1075-1089.	3.9	104
49	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. Acta Neuropathologica, 2019, 138, 827-835.	3.9	42
50	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. Cell Reports, 2019, 29, 2338-2354.e7.	2.9	74
51	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathologica Communications, 2019, 7, 163.	2.4	37
52	YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. Nature Communications, 2019, 10, 3914.	5.8	65
53	Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells. PLoS ONE, 2019, 14, e0210665.	1.1	5
54	GENE-13. PEDIATRIC MENINGIOMAS ARE CHARACTERIZED BY DISTINCT METHYLATION PROFILES DIFFERENT FROM ADULT MENINGIOMAS. Neuro-Oncology, 2019, 21, ii83-ii84.	0.6	0

#	Article	IF	Citations
55	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathologica, 2019, 138, 309-326.	3.9	180
56	Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells. Blood Advances, 2019, 3, 1092-1102.	2.5	25
57	Acyl-CoA-Binding Protein Drives Glioblastoma Tumorigenesis by Sustaining Fatty Acid Oxidation. Cell Metabolism, 2019, 30, 274-289.e5.	7.2	115
58	Molecular progression of SHH-activated medulloblastomas. Acta Neuropathologica, 2019, 138, 327-330.	3.9	2
59	Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles. Acta Neuropathologica, 2019, 137, 1003-1015.	3.9	9
60	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. Acta Neuropathologica, 2019, 137, 837-846.	3.9	43
61	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	13.7	94
62	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. Cancer Cell, 2019, 35, 95-110.e8.	7.7	65
63	Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. Acta Neuropathologica, 2019, 137, 521-525.	3.9	51
64	Integrated molecular characterization of <scp>IDH</scp>â€mutant glioblastomas. Neuropathology and Applied Neurobiology, 2019, 45, 108-118.	1.8	68
65	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. Clinical Cancer Research, 2019, 25, 1851-1866.	3.2	55
66	DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. Neuro-Oncology, 2019, 21, 214-221.	0.6	31
67	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	3.9	298
68	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathologica, 2018, 135, 635-638.	3.9	17
69	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature, 2018, 553, 101-105.	13.7	170
70	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	13.7	1,872
71	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	3.9	190
72	Molecular characterization of medulloblastomas with extensive nodularity (MBEN). Acta Neuropathologica, 2018, 136, 303-313.	3.9	20

#	Article	IF	Citations
73	Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3392-3397.	3.3	34
74	Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathology, 2018, 28, 656-662.	2.1	89
75	Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors. Nature Communications, 2018, 9, 4760.	5.8	66
76	A biobank of patient-derived pediatric brain tumor models. Nature Medicine, 2018, 24, 1752-1761.	15.2	124
77	Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. Cancer Cell, 2018, 34, 379-395.e7.	7.7	104
78	Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2018, 34, 396-410.e8.	7.7	146
79	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncology, The, 2018, 19, 768-784.	5.1	151
80	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathologica, 2018, 136, 239-253.	3.9	118
81	Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas. Modern Pathology, 2018, 31, 1490-1501.	2.9	29
82	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. Acta Neuropathologica, 2018, 136, 293-302.	3.9	56
83	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathologica, 2018, 136, 181-210.	3.9	308
84	Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations. Molecular Cancer Research, 2018, 16, 1491-1498.	1.5	39
85	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	3.9	86
86	Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. Acta Neuropathologica, 2018, 136, 339-343.	3.9	37
87	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	5.1	268
88	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathologica, 2018, 136, 327-337.	3.9	104
89	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathologica, 2018, 136, 211-226.	3.9	199
90	Genetic confirmation that ependymoma can arise as part of multiple endocrine neoplasia type 1 (MEN1) syndrome. Acta Neuropathologica, 2017, 133, 661-663.	3.9	11

#	Article	IF	Citations
91	Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. Leukemia, 2017, 31, 2048-2056.	3.3	47
92	Spatial heterogeneity in medulloblastoma. Nature Genetics, 2017, 49, 780-788.	9.4	112
93	H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathologica, 2017, 134, 507-516.	3.9	144
94	Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. Oncogene, 2017, 36, 5231-5242.	2.6	43
95	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro-Oncology, 2017, 19, 1607-1617.	0.6	39
96	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro-Oncology, 2017, 19, 1183-1194.	0.6	31
97	Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme. Nature Communications, 2017, 8, 14758.	5.8	118
98	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. Acta Neuropathologica, 2017, 133, 325-327.	3.9	12
99	DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. Acta Neuropathologica, 2017, 134, 965-967.	3.9	38
100	A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors. Nature Medicine, 2017, 23, 1191-1202.	15.2	38
101	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	13.7	787
102	HGNET-BCOR Tumors of the Cerebellum. American Journal of Surgical Pathology, 2017, 41, 1254-1260.	2.1	49
103	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathologica, 2017, 134, 705-714.	3.9	168
104	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 2017, 133, 5-12.	3.9	271
105	Quantification of telomere features in tumor tissue sections by an automated 3D imaging-based workflow. Methods, 2017, 114, 60-73.	1.9	15
106	Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1â€deficient nonâ€rhabdoid tumor with favorable longâ€term outcome. Brain Pathology, 2017, 27, 411-418.	2.1	58
107	Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification. PLoS ONE, 2017, 12, e0178351.	1.1	15
108	Droplet digital PCR is a powerful technique to demonstrate frequent FGFR1 duplication in dysembryoplastic neuroepithelial tumors. Oncotarget, 2017, 8, 2104-2113.	0.8	39

#	Article	IF	Citations
109	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Oncotarget, 2017, 8, 11460-11479.	0.8	43
110	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. Brain Pathology, 2016, 26, 506-516.	2.1	14
111	Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomasâ€"Same Entity or First Cousins?. Brain Pathology, 2016, 26, 215-223.	2.1	95
112	Differential nuclear <scp>ATRX</scp> expression in sarcomas. Histopathology, 2016, 68, 738-745.	1.6	19
113	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. Brain Pathology, 2016, 26, 199-205.	2.1	39
114	Telomere dysfunction and chromothripsis. International Journal of Cancer, 2016, 138, 2905-2914.	2.3	42
115	Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas. Genes Chromosomes and Cancer, 2016, 55, 418-427.	1.5	34
116	FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. EMBO Journal, 2016, 35, 2192-2212.	3.5	58
117	Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. Acta Neuropathologica, 2016, 132, 149-151.	3.9	127
118	Nestin Mediates Hedgehog Pathway Tumorigenesis. Cancer Research, 2016, 76, 5573-5583.	0.4	28
119	Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nature Medicine, 2016, 22, 1314-1320.	15.2	183
120	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	0.8	160
121	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature, 2016, 530, 57-62.	13.7	318
122	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	13.7	266
123	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathologica, 2016, 131, 903-910.	3.9	203
124	Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients. Journal of Neuropathology and Experimental Neurology, 2016, 75, 408-414.	0.9	35
125	Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells. American Journal of Pathology, 2016, 186, 446-459.	1.9	32
126	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. Neuro-Oncology, 2016, 18, 790-796.	0.6	67

#	Article	IF	Citations
127	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	7.7	438
128	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	13.5	702
129	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	5.1	274
130	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathologica, 2016, 131, 137-146.	3.9	162
131	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. Oncotarget, 2016, 7, 61860-61873.	0.8	27
132	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. Neuropathology, 2015, 35, 538-544.	0.7	38
133	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743.	7.7	933
134	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathologica, 2015, 130, 419-434.	3.9	74
135	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathologica, 2015, 129, 867-873.	3.9	272
136	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nature Communications, 2015, 6, 10001.	5.8	266
137	Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathologica, 2015, 129, 449-457.	3.9	80
138	Ependymoma. Molecular Pathology Library, 2015, , 67-75.	0.1	0
139	Long-term survival in a case of ETANTR with histological features of neuronal maturation after therapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 603-607.	1.4	19
140	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathologica, 2015, 129, 669-678.	3.9	277
141	Intraocular Medulloepitheliomas and Embryonal Tumors With Multilayered Rosettes of the Brain: Comparative Roles of LIN28A and C19MC. American Journal of Ophthalmology, 2015, 159, 1065-1074.e1.	1.7	28
142	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica, 2015, 130, 407-417.	3.9	237
143	Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nature Communications, 2015, 6, 7391.	5.8	244
144	Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathologica Communications, 2015, 3, 22.	2.4	66

#	Article	IF	Citations
145	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. Clinical Cancer Research, 2015, 21, 3750-3758.	3.2	40
146	<scp>P</scp>aired box gene 8 (<scp>PAX8</scp>) expression is associated with sonic hedgehog (<scp>SHH</scp>)/wingless int (<scp>WNT</scp>) subtypes, desmoplastic histology and patient survival in human medulloblastomas. Neuropathology and Applied Neurobiology, 2015, 41, 165-179.	1.8	4
147	Medulloepithelioma with peculiar clinical presentation, stem cell phenotype and aberrant DNA-methylation profile. CNS Oncology, 2015, 4, 203-212.	1.2	3
148	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an â€œintegratedâ€•diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathologica, 2015, 129, 133-146.	3.9	378
149	Foretinib Is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma. Cancer Research, 2015, 75, 134-146.	0.4	51
150	Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age. Oncotarget, 2015, 6, 31844-31856.	0.8	14
151	Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathologica, 2014, 128, 733-741.	3.9	116
152	Overcoming multiple drug resistance mechanisms in medulloblastoma. Acta Neuropathologica Communications, 2014, 2, 57.	2.4	49
153	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathologica Communications, 2014, 2, 174.	2.4	37
154	Targeting Self-Renewal in High-Grade Brain Tumors Leads to Loss of Brain Tumor Stem Cells and Prolonged Survival. Cell Stem Cell, 2014, 15, 185-198.	5.2	123
155	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature, 2014, 506, 445-450.	13.7	521
156	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	7.7	627
157	Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathologica, 2014, 128, 137-149.	3.9	125
158	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature, 2014, 510, 537-541.	13.7	378
159	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathologica, 2014, 128, 279-289.	3.9	191
160	Spinal metastasis of gliosarcoma: Array-based comparative genomic hybridization for confirmation of metastatic spread. Journal of Clinical Neuroscience, 2014, 21, 1945-1950.	0.8	8
161	The Shh Receptor Boc Promotes Progression of Early Medulloblastoma to Advanced Tumors. Developmental Cell, 2014, 31, 34-47.	3.1	43
162	<scp>I</scp>nternational <scp>S</scp>ociety of <scp>N</scp>europathologyâ€•<scp>H</scp>aarlem <scp>C</scp>onsensus <scp>G</scp>uidelines for <scp>N</scp>ervous <scp>S</scp>ystem <scp>T</scp>umor <scp>C</scp>lassification and <scp>G</scp>rading. Brain Pathology, 2014, 24, 429-435.	2.1	499

#	Article	IF	Citations
163	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	0.8	263
164	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro-Oncology, 2014, 16, 1408-1416.	0.6	175
165	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 2014, 128, 561-571.	3.9	176
166	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature, 2014, 511, 428-434.	13.7	520
167	Quiescent Sox2+ Cells Drive Hierarchical Growth and Relapse in Sonic Hedgehog Subgroup Medulloblastoma. Cancer Cell, 2014, 26, 33-47.	7.7	241
168	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932.	9.4	674
169	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathologica, 2013, 126, 443-451.	3.9	304
170	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathologica, 2013, 125, 913-916.	3.9	244
171	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathologica, 2013, 125, 373-384.	3.9	169
172	Emerging Insights into the Ependymoma Epigenome. Brain Pathology, 2013, 23, 206-209.	2.1	21
173	Hypermutation of the Inactive X Chromosome Is a Frequent Event in Cancer. Cell, 2013, 155, 567-581.	13.5	67
174	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 2013, 126, 907-915.	3.9	254
175	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	5.1	307
176	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 2013, 24, 660-672.	7.7	633
177	Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. Neuro-Oncology, 2013, 15, 1644-1651.	0.6	73
178	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. Cell, 2013, 153, 1064-1079.	13.5	348
179	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathologica, 2013, 125, 659-669.	3.9	250
180	BAF complexes facilitate decatenation of DNA by topoisomerase IIÎ±. Nature, 2013, 497, 624-627.	13.7	230

#	Article	IF	Citations
181	Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. Acta Neuropathologica, 2013, 126, 291-301.	3.9	84
182	Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. Child's Nervous System, 2013, 29, 1253-1262.	0.6	12
183	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	3.9	146
184	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. Journal of Clinical Oncology, 2013, 31, 2927-2935.	0.8	381
185	Molecular approaches to ependymoma. Current Opinion in Neurology, 2012, 25, 745-750.	1.8	22
186	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	13.7	761
187	Medulloblastomics: the end of the beginning. Nature Reviews Cancer, 2012, 12, 818-834.	12.8	560
188	Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathologica, 2012, 124, 615-625.	3.9	376
189	Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathologica, 2012, 123, 615-626.	3.9	318
190	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathologica, 2012, 124, 439-447.	3.9	799
191	LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathologica, 2012, 124, 875-881.	3.9	115
192	DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis. Journal of Neuro-Oncology, 2012, 109, 415-423.	1.4	13
193	HD-MB03 is a novel GroupÂ3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. Journal of Neuro-Oncology, 2012, 110, 335-348.	1.4	110
194	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	7.7	1,551
195	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. Cell, 2012, 148, 59-71.	13.5	743
196	Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncology, The, 2012, 13, 838-848.	5.1	148
197	Nestin Expression Identifies Ependymoma Patients with Poor Outcome. Brain Pathology, 2012, 22, 848-860.	2.1	40
198	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	13.7	2,129

#	Article	IF	Citations
199	The RNA-Binding Protein Musashi1 Affects Medulloblastoma Growth via a Network of Cancer-Related Genes and Is an Indicator of Poor Prognosis. American Journal of Pathology, 2012, 181, 1762-1772.	1.9	73
200	Update on molecular and genetic alterations in adult medulloblastoma. Memo - Magazine of European Medical Oncology, 2012, 5, 228-232.	0.3	29
201	ICGC PedBrain - dissecting the genomic complexity underlying medulloblastoma using whole-genome sequencing. BMC Proceedings, 2012, 6, .	1.8	1
202	The clinical implications of medulloblastoma subgroups. Nature Reviews Neurology, 2012, 8, 340-351.	4.9	261
203	Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature, 2012, 482, 529-533.	13.7	376
204	Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, 488, 100-105.	13.7	765
205	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathologica, 2012, 123, 515-527.	3.9	66
206	Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 2012, 123, 465-472.	3.9	1,536
207	MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathologica, 2012, 123, 501-513.	3.9	87
208	MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathologica, 2012, 123, 529-538.	3.9	60
209	An essential role for p38 MAPK in cerebellar granule neuron precursor proliferation. Acta Neuropathologica, 2012, 123, 573-586.	3.9	19
210	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica, 2012, 123, 473-484.	3.9	863
211	Hedgehog-mediated regulation of PPARÎ³ controls metabolic patterns in neural precursors and shh-driven medulloblastoma. Acta Neuropathologica, 2012, 123, 587-600.	3.9	43
212	An Animal Model of MYC-Driven Medulloblastoma. Cancer Cell, 2012, 21, 155-167.	7.7	267
213	Progressively Metastasizing Ependymoma: Genomic Aberrations. , 2012, , 297-306.		0
214	Adult Medulloblastoma Comprises Three Major Molecular Variants. Journal of Clinical Oncology, 2011, 29, 2717-2723.	0.8	215
215	The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations. Brain Pathology, 2011, 21, 74-87.	2.1	150
216	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. Cancer Cell, 2011, 20, 143-157.	7.7	494

#	Article	IF	Citations
217	Absence of chromosome 19q13.41 amplification in a case of atypical teratoid/rhabdoid tumor with ependymoblastic differentiation. Acta Neuropathologica, 2011, 121, 283-285.	3.9	8
218	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathologica, 2011, 121, 397-405.	3.9	914
219	Oncogenic FAM131Bâ€“BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathologica, 2011, 121, 763-774.	3.9	211
220	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathologica, 2011, 122, 231-240.	3.9	195
221	A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathologica, 2011, 122, 637-650.	3.9	77
222	Embryonal tumor with abundant neuropil and true rosettes (ETANTR) with loss of morphological but retained genetic key features during progression. Acta Neuropathologica, 2011, 122, 787-790.	3.9	27
223	Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. International Journal of Cancer, 2011, 129, 2297-2303.	2.3	75
224	FSTL5 Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. Journal of Clinical Oncology, 2011, 29, 3852-3861.	0.8	143
225	Medulloblastoma Comprises Four Distinct Molecular Variants. Journal of Clinical Oncology, 2011, 29, 1408-1414.	0.8	1,131
226	Reply to J.C. Lindsey et al. Journal of Clinical Oncology, 2011, 29, e348-e349.	0.8	2
227	Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas. Clinical Cancer Research, 2011, 17, 4650-4660.	3.2	135
228	The Transcription Factor Evi-1 Is Overexpressed, Promotes Proliferation, and Is Prognostically Unfavorable in Infratentorial Ependymomas. Clinical Cancer Research, 2011, 17, 3631-3637.	3.2	34
229	Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro-Oncology, 2011, 13, 866-879.	0.6	67
230	An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. Journal of Clinical Investigation, 2011, 121, 1344-1348.	3.9	68
231	Sorafenib Plus Valproic Acid for Infant Spinal Glioblastoma. Journal of Pediatric Hematology/Oncology, 2010, 32, 511-514.	0.3	11
232	Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathologica, 2010, 120, 253-260.	3.9	129
233	Molecular diagnostics of CNS embryonal tumors. Acta Neuropathologica, 2010, 120, 553-566.	3.9	83
234	Characterization of R132H Mutationâ€specific IDH1 Antibody Binding in Brain Tumors. Brain Pathology, 2010, 20, 245-254.	2.1	463

#	Article	IF	Citations
235	Molecular Staging of Intracranial Ependymoma in Children and Adults. Journal of Clinical Oncology, 2010, 28, 3182-3190.	0.8	210
236	TP53 Mutation Is Frequently Associated With CTNNB1 Mutation or MYCN Amplification and Is Compatible With Long-Term Survival in Medulloblastoma. Journal of Clinical Oncology, 2010, 28, 5188-5196.	0.8	100
237	Role of LIM and SH3 Protein 1 (LASP1) in the Metastatic Dissemination of Medulloblastoma. Cancer Research, 2010, 70, 8003-8014.	0.4	62
238	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. Clinical Cancer Research, 2010, 16, 3240-3252.	3.2	175
239	Adult and Pediatric Medulloblastomas Are Genetically Distinct and Require Different Algorithms for Molecular Risk Stratification. Journal of Clinical Oncology, 2010, 28, 3054-3060.	0.8	136
240	Abstract 4347: Medulloblastoma comprises four distinct diseases. , 2010, , .		6
241	Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and the MYC and MYCN Loci. Journal of Clinical Oncology, 2009, 27, 1627-1636.	0.8	274
242	Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. Genes Chromosomes and Cancer, 2009, 48, 229-238.	1.5	24
243	Novel oncogene amplifications in tumors from a family with Liâ€“Fraumeni syndrome. Genes Chromosomes and Cancer, 2009, 48, 558-568.	1.5	13
244	Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathologica, 2009, 117, 457-464.	3.9	106
245	Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathologica, 2009, 118, 401-405.	3.9	255
246	Accumulation of genomic aberrations during clinical progression of medulloblastoma. Acta Neuropathologica, 2008, 116, 383-390.	3.9	23
247	Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica, 2008, 116, 597-602.	3.9	910
248	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. Journal of Clinical Investigation, 2008, 118, 1739-1749.	3.9	437
249	Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of theCDKN2A locus and other genomic aberrations distinct from medulloblastomas. Genes Chromosomes and Cancer, 2007, 46, 839-851.	1.5	76
250	Genetically distinct and clinically relevant subtypes of glioblastoma defined by array-based comparative genomic hybridization (array-CGH). Acta Neuropathologica, 2006, 111, 465-474.	3.9	47
251	Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats. Genes Chromosomes and Cancer, 2006, 45, 401-410.	1.5	41
252	Identification of Gains on 1q and Epidermal Growth Factor Receptor Overexpression as Independent Prognostic Markers in Intracranial Ependymoma. Clinical Cancer Research, 2006, 12, 2070-2079.	3.2	212

#	Article	IF	Citations
253	Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Modern Pathology, 2005, 18, 1258-1263.	2.9	50
254	Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma. Journal of Clinical Oncology, 2005, 23, 8853-8862.	0.8	207
255	Microarray-Based Screening for Molecular Markers in Medulloblastoma Revealed STK15 as Independent Predictor for Survival. Cancer Research, 2004, 64, 3103-3111.	0.4	139
256	The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era. Cancer, 2004, 100, 1230-1237.	2.0	124
257	Gene Expression Patterns in Ependymomas Correlate with Tumor Location, Grade, and Patient Age. American Journal of Pathology, 2003, 163, 1721-1727.	1.9	149
258	Immunohistochemical markers for prognosis of ependymal neoplasms. Journal of Neuro-Oncology, 2002, 58, 255-270.	1.4	64
259	Immunohistochemical markers for intracranial ependymoma recurrence. Journal of the Neurological Sciences, 2000, 177, 72-82.	0.3	66